Aging Is Treatable. Medicine Hasn't Caught Up Yet.

In 2014, researchers at the Buck Institute showed that rapamycin could extend lifespan in mice by up to 25%. In 2016, a team at Mayo Clinic demonstrated that clearing senescent cells from aging mice made them healthier and longer-lived. By 2020, the basic science of aging had produced a clear picture: aging is not mysterious entropy. It's a set of identifiable biological processes that can be slowed, paused, or partially reversed.

It's now 2026, and almost none of this knowledge has reached your doctor's office.

What Aging Biology Has Proven

The science is not speculative. The major hallmarks of aging have been identified and replicated across labs worldwide:

mTOR overactivation: The mTOR pathway, which promotes cell growth, becomes chronically overactive with age. This shifts cells from repair mode to growth mode, accelerating tissue deterioration. Rapamycin inhibits mTOR and extends lifespan in every model organism tested -- yeast, worms, flies, and mice.

Cellular senescence: As cells age, some enter a "zombie" state: they stop dividing but don't die. These senescent cells accumulate and secrete inflammatory compounds that damage surrounding tissue. Senolytic drugs (like dasatinib + quercetin) can selectively clear these cells.

NAD+ decline: NAD+ is a coenzyme essential for cellular energy production and DNA repair. Its levels drop with age. Precursors like NMN and NR can raise NAD+ levels, though the clinical significance of doing so is still being studied.

Epigenetic drift: The patterns of gene expression that define cell identity gradually degrade with age. Yamanaka factors can partially reprogram these patterns in animal models, though this remains far from clinical application.

Why Your Doctor Doesn't Know This

The gap between aging biology and clinical medicine is not a knowledge gap among researchers. It's a structural gap in how medicine is organized:

Aging is not an FDA-recognized disease. This is the fundamental barrier. The FDA approves drugs for specific diseases. Aging is not classified as one. This means no pharmaceutical company can run a trial with "aging" as the endpoint, get approval, and market a drug for it. No approved indication means no insurance coverage means no standard prescribing protocol.

Medical education doesn't cover longevity. Most physicians receive zero hours of training in aging biology during residency. They learn to treat the diseases of aging (heart disease, cancer, diabetes) but not the underlying process that drives all of them.

No financial incentive for pharma. A longevity drug that worked for everyone would be the most valuable pharmaceutical product ever created. But without an FDA-approvable indication, there's no clear path to market. Pharma companies have little incentive to fund longevity trials when they can fund cancer or obesity trials with well-defined regulatory endpoints.

The TAME trial impasse. The Targeting Aging with Metformin (TAME) trial was designed to be a proof-of-concept: show the FDA that a drug can delay multiple age-related conditions simultaneously, establishing "aging" as a valid clinical endpoint. It's been in development for years, facing chronic underfunding. If it succeeds, it could open the door for longevity drugs. But "if" and "when" are very different words.

What Informed Patients Are Doing Now

A growing community of patients and clinicians isn't waiting for the FDA to reclassify aging. They're working within the existing system:

Off-label rapamycin: Rapamycin is FDA-approved for organ transplant rejection. Physicians can legally prescribe it off-label for any purpose they deem medically appropriate. A small but growing number of clinicians prescribe low-dose rapamycin (typically 1-6mg weekly, compared to the daily immunosuppressive doses used in transplant) for patients interested in mTOR inhibition. Topical rapamycin focuses this approach on the skin specifically, avoiding systemic exposure.

Senolytics: Dasatinib (an FDA-approved cancer drug) combined with quercetin (a supplement) is the most-studied senolytic regimen. Some clinicians prescribe intermittent courses, though long-term human safety data at these doses is limited.

NAD+ precursors: NMN and NR are available as supplements and do not require a prescription. Whether raising NAD+ levels translates to meaningful health outcomes in humans is still an open question.

Comprehensive biomarker tracking: Patients interested in longevity increasingly track biological age markers (epigenetic clocks, inflammatory markers, metabolic panels) to measure the impact of interventions.

The Honest Limitations

We should be direct about what we don't know:

No longevity intervention has been proven to extend human lifespan. The animal data is compelling, but humans are not mice. Rapamycin, senolytics, NAD+ precursors, and other interventions are being used based on mechanistic reasoning and preclinical evidence, not on completed human longevity trials.

The safety profiles of these interventions at longevity-relevant doses in healthy adults are not fully characterized. Rapamycin at immunosuppressive doses has well-known risks. At low intermittent doses, the risk profile appears different, but "appears different" is not "proven safe."

This is an area where risk tolerance, individual health status, and clinician judgment matter enormously. Anyone considering longevity interventions should work with a provider who understands both the science and the limitations.

The Bottom Line

The science of aging has produced actionable insights that mainstream medicine hasn't absorbed. This isn't because the science is weak -- it's because the regulatory, economic, and educational structures of medicine weren't designed for it.

The question is not whether aging biology is real. It is. The question is how long it will take for the system to catch up, and what informed patients should do in the meantime.

We believe the answer is: engage with the evidence honestly, work with clinicians who understand the landscape, and make individual decisions based on the best available data rather than waiting for a system that may take another decade to adapt.